- Home
- ESQ vs PHAR Comparison
ESQ vs PHAR Comparison
Compare ESQ & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ESQ | PHAR |
|---|---|---|
| Founded | 2006 | 1988 |
| Country | United States | Netherlands |
| Employees | 151 | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 910.9M | 1.1B |
| IPO Year | 2017 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ESQ | PHAR |
|---|---|---|
| Price | $109.72 | $16.12 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $120.33 | $39.00 |
| AVG Volume (30 Days) | ★ 71.3K | 18.4K |
| Earning Date | 04-23-2026 | 03-12-2026 |
| Dividend Yield | ★ 0.76% | N/A |
| EPS Growth | ★ 14.20 | N/A |
| EPS | ★ 5.87 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $28.65 | $10.04 |
| Revenue Next Year | $4.95 | $2.70 |
| P/E Ratio | ★ $17.97 | $3,041.22 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $69.14 | $7.50 |
| 52 Week High | $119.86 | $21.34 |
Technical Indicators
Market Signals| Indicator | ESQ | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 54.71 | 48.33 |
| Support Level | $91.62 | $14.88 |
| Resistance Level | $112.17 | $17.29 |
| Average True Range (ATR) | 3.81 | 0.69 |
| MACD | 0.67 | 0.05 |
| Stochastic Oscillator | 66.04 | 45.74 |
Price Performance
Historical ComparisonAbout ESQ Esquire Financial Holdings Inc.
Esquire Financial Holdings Inc is a financial holding company operating as a full service commercial bank. It serves the financial needs of the litigation industry and small businesses nationally, as well as commercial and retail customers in the New York metropolitan area. The bank offers tailored financial and payment processing solutions to the litigation community and their clients as well as dynamic and flexible payment processing solutions to small business owners. It operates in one operating segment, that of community banking.
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.